Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT07667205Enrolling by invitationPhase 1
Liposomal vs. ferrous iron for preventing anemia in preterm babies
This trial compares two types of iron supplements—liposomal iron and ferrous iron—to see which works better at preventing iron deficiency anemia in premature infants. It aims to find a safer or more effective option for these fragile newborns.
CairoAges 2 weeks–3 weeks - NCT07671378RecruitingPhase 2
Study of zanubrutinib plus sonrotoclax for high-risk CLL/SLL
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
Nanjing, JiangsuAges 18–75 - NCT07670949Recruiting
68Ga-EV203 imaging for blood cancers
This trial uses a special imaging agent called 68Ga-EV203 to see where certain blood cancers (multiple myeloma, non-Hodgkin lymphoma, or acute myeloid leukemia) are located in the body. It helps doctors understand how the agent spreads and how safe it is.
Hangzhou, ZhejiangAges 18–75 - NCT07665307Recruiting
Delayed side effects after CAR-T for multiple myeloma
This study looks at late side effects that may happen after CAR-T therapy (cilta-cel) for multiple myeloma. It aims to better understand these delayed toxicities so doctors can manage them more effectively.
San Francisco, CaliforniaAges 18 years+ - NCT07663864RecruitingPhase 1/Phase 2
Luspatercept for anemia after AML treatment
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
Guangzhou, GuangdongAges 18–60 - NCT07671209Recruiting
Cancer care support for patients with leukemia
This trial studies how screening for social needs (like housing, food, or transportation) and offering early help can improve care for adults with leukemia. It is for patients newly referred to a leukemia clinic.
Boston, MassachusettsAges 18 years+ - NCT07670130Recruiting
Venetoclax TDM in Newly Diagnosed AML: Response and Outlook
This study looks at how the drug venetoclax works in people newly diagnosed with acute myeloid leukemia (AML). It helps doctors understand the right dose for better results.
SuzhouAges 16 years+ - NCT06673498RecruitingPhase 2
Two drugs to raise platelets before surgery in liver disease
This trial tests two medications (lusutrombopag and recombinant human thrombopoietin) given together to raise platelet levels before a planned surgery in people with chronic liver disease. The goal is to reduce the need for platelet transfusions and make the procedure safer.
Fuyang, AnhuiAges 18 years+ - NCT06395870RecruitingPhase 1
Dual-target cell therapy for returning B-cell lymphoma
This trial tests a new cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is for patients whose B-cell non-Hodgkin lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this therapy can help control the cancer.
Hefei, AnhuiAges 18–75 - NCT06073860Recruiting
Safety study of Luspatercept for MDS or thalassemia in Korea
This study is checking the safety of a drug called Luspatercept (brand name Reblozyl) for people in Korea who have myelodysplastic syndrome (a blood disorder) or beta-thalassemia (a type of inherited anemia). It is designed to monitor how safe the drug is when used as prescribed by your doctor.
SeoulAges 19 years+ - NCT06073847Recruiting
Safety study of fedratinib in Korean patients with myelofibrosis
This study looks at the safety of the drug fedratinib in Korean patients with myelofibrosis. It will help doctors better understand how well patients tolerate the drug when it's used as approved.
SeoulAges 19 years+ - NCT05196789Recruiting
Genetic testing to diagnose inherited bone marrow failure
This study looks at patients with suspected inherited (families-linked) bone marrow failure to better understand the cause using genetic testing. It may help confirm a diagnosis and refine how different inherited conditions are classified.
Melbourne, VictoriaAges 3 months+ - NCT06512519Recruiting
Second stem cell transplant for graft failure
This trial tests a second transplant using a half-matched donor for people whose first transplant failed. It may help if you have a blood cancer and are otherwise healthy enough for another procedure.
Beijing, Beijing MunicipalityAges 14 years+ - NCT07661537RecruitingPhase 1
Study of SHR-3079 for B-cell Non-Hodgkin Lymphoma
This trial tests a new drug called SHR-3079 for people with B-cell non-Hodgkin lymphoma whose cancer did not get better or came back after at least one standard treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07656415RecruitingPhase 3
Study of mitapivat for sickle cell disease patients who need blood transfusions
This study tests whether a daily pill called mitapivat can reduce the number of blood transfusions you need. It is for people with sickle cell disease who have had at least one transfusion in the past year and are not on regular transfusion therapy.
Indianapolis, IndianaAges 12 years+ - NCT07657052Enrolling by invitation
Long-term safety and effectiveness of XH-S003 for PNH
This study tests if the drug XH-S003 is safe and works well over a long period for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. If you've already taken XH-S003 in a past study and your doctor thinks it helped, you may join to keep getting the treatment.
Tianjin, JinanAges 18 years+ - NCT07658443Enrolling by invitation
Evaluating DFPP for microplastic reduction
This trial tests whether DFPP, a blood filtration treatment you may already be receiving, can reduce microplastics in your blood. If you are already scheduled for DFPP, you may help us learn more about its benefits.
ObergünzburgAges 18–80 - NCT04655092RecruitingPhase 3
Extension study for people finishing prior P1101 treatment
This is an “extension” trial for people who already completed a 52-week P1101 study and agreed to continue. It tests whether continuing P1101 after the original study is safe and beneficial for certain patients.
Toon-shi, EhimeAges 20 years+ - NCT06678282Recruiting
Testing an investigational cell therapy for B-cell lymphoma or leukemia
This trial tests a new cell therapy (JY231) for people with B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or didn't respond to previous treatments. The therapy targets a marker on cancer cells called CD19 and aims to help your body fight the cancer.
Zhenzhou, HenanAges 18–75 - NCT07657312RecruitingPhase 2
Infliximab to prevent side effects during myeloma treatment
This trial tests if infliximab, a drug that calms the immune system, can prevent cytokine release syndrome (a serious side effect) when patients receive teclistamab or talquetamab for multiple myeloma that has returned or not responded to treatment.
Columbus, OhioAges 18 years+ - NCT07658989Recruiting
Blood thinners in pregnancy with mechanical heart valves
This study looks at the best way to manage blood thinners for pregnant people who have mechanical heart valves. It aims to find the safest approach for both the mother and the baby.
Toronto, OntarioAges 18–45 - NCT07657793RecruitingPhase 2/Phase 3
Sirolimus for Lupus-Related Low Platelets
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
Beijing, Beijing MunicipalityAges 18–65 - NCT07663253Recruiting
Isatuximab with VRd for newly diagnosed multiple myeloma patients not eligible for transplant
This trial tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone—for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding isatuximab helps control the cancer better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07660939RecruitingPhase 1
GPRC5D PET/CT scan for plasma cell disorders
This study uses a special PET/CT scan to look for a protein called GPRC5D in people with plasma cell disorders (like multiple myeloma). The scan might help doctors see where the disease is in the body. Healthy volunteers can also join to help compare results.
Beijing, Beijing MunicipalityAges 18–80
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.